42.24
전일 마감가:
$42.15
열려 있는:
$42.34
하루 거래량:
887.85K
Relative Volume:
0.53
시가총액:
$6.72B
수익:
$705.14M
순이익/손실:
$-453.90M
주가수익비율:
-13.90
EPS:
-3.04
순현금흐름:
$-551.29M
1주 성능:
+1.16%
1개월 성능:
+5.61%
6개월 성능:
+21.57%
1년 성능:
-18.54%
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
명칭
Ionis Pharmaceuticals Inc
전화
(760) 931-9200
주소
2855 GAZELLE COURT, CARLSBAD, CA
IONS을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
IONS
Ionis Pharmaceuticals Inc
|
42.24 | 6.71B | 705.14M | -453.90M | -551.29M | -3.04 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-01 | 업그레이드 | Barclays | Equal Weight → Overweight |
2025-04-07 | 개시 | H.C. Wainwright | Buy |
2025-03-31 | 개시 | Redburn Atlantic | Neutral |
2024-08-02 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
2024-07-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
2024-07-16 | 재개 | Jefferies | Buy |
2024-06-14 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
2024-04-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
2024-01-02 | 업그레이드 | BofA Securities | Neutral → Buy |
2023-10-23 | 업그레이드 | BofA Securities | Underperform → Neutral |
2023-09-29 | 개시 | Raymond James | Strong Buy |
2023-07-31 | 업그레이드 | Citigroup | Neutral → Buy |
2023-06-07 | 재개 | Piper Sandler | Overweight |
2023-05-04 | 업그레이드 | Citigroup | Sell → Neutral |
2023-03-21 | 개시 | Bernstein | Underperform |
2022-12-21 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2022-09-09 | 재개 | Morgan Stanley | Overweight |
2022-07-18 | 재개 | Oppenheimer | Outperform |
2022-03-31 | 재개 | Piper Sandler | Overweight |
2022-03-01 | 개시 | Citigroup | Sell |
2022-03-01 | 개시 | Guggenheim | Buy |
2022-02-01 | 다운그레이드 | BofA Securities | Buy → Underperform |
2021-12-14 | 업그레이드 | William Blair | Mkt Perform → Outperform |
2021-05-07 | 업그레이드 | UBS | Sell → Neutral |
2021-03-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
2020-12-16 | 개시 | UBS | Sell |
2020-12-15 | 업그레이드 | Cowen | Market Perform → Outperform |
2020-09-14 | 재개 | JP Morgan | Neutral |
2020-09-02 | 개시 | The Benchmark Company | Hold |
2020-06-01 | 재개 | Oppenheimer | Outperform |
2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
2020-03-05 | 개시 | Citigroup | Buy |
2019-12-13 | 개시 | Oppenheimer | Outperform |
2019-11-13 | 개시 | BofA/Merrill | Buy |
2019-11-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
2019-09-10 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
2018-08-08 | 재확인 | Stifel | Hold |
2018-08-07 | 재확인 | Stifel | Hold |
2018-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
2017-10-06 | 재개 | Goldman | Sell |
2017-08-17 | 개시 | Evercore ISI | Outperform |
2017-08-09 | 재확인 | Stifel | Hold |
2017-03-10 | 다운그레이드 | Goldman | Neutral → Sell |
2016-12-28 | 재확인 | BMO Capital Markets | Outperform |
2016-12-27 | 재확인 | Leerink Partners | Mkt Perform |
모두보기
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
KalVista, Biogen, Ionis get EU positive opinions for key drugs (KALV:NASDAQ) - Seeking Alpha
Is Ionis Pharmaceuticals Inc. a good long term investmentBreakthrough capital growth - Autocar Professional
TRYNGOLZA Receives EU CHMP Approval Recommendation for Rare Disease FCS Treatment | IONS Stock News - Stock Titan
Ionis Pharmaceuticals Inc. Stock Analysis and ForecastRemarkably fast returns - jammulinksnews.com
Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Ionis Pharmaceuticals founder Stanley Crooke on the fight against rare diseases - MSN
What analysts say about Ionis Pharmaceuticals Inc. stockRapid portfolio appreciation - Autocar Professional
What drives Ionis Pharmaceuticals Inc. stock priceHigh-profit trading signals - jammulinksnews.com
Lou Gehrig’s Disease Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corpo - Barchart.com
Pinning Down Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) P/S Is Difficult Right Now - 富途牛牛
Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025 - GlobeNewswire Inc.
Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com
Ionis HAE drug shows strong results in switch study - Investing.com Australia
Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice - Yahoo Finance
Global Motor Neuron Disease Treatment Market to Exhibit Substantial Growth at a CAGR of ~6% by 2032 | DelveInsight - Yahoo Finance
Hutchinson-Gilford Progeria Syndrome Market Driven - openPR.com
(IONS) Technical Data - news.stocktradersdaily.com
Ionis Pharmaceuticals to Host Q2 2025 Earnings Webcast on July 30th - AInvest
Ionis to hold second quarter 2025 financial results webcast - Business Wire
Ionis To Hold Second Quarter 2025 Financial Results Webcast - Barchart.com
Ionis Pharma CEO Monia sells $48,416 in stock By Investing.com - Investing.com Canada
Ionis Pharmaceuticals CEO Monia Brett Sells 1160 Shares at $41.74 - AInvest
Multiple System Atrophy Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail
Spinocerebellar Ataxias Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc, Biohaven Pharma - Barchart.com
Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock, Raises PT - Insider Monkey
11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds - Insider Monkey
Ionis Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress - Investing.com
Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire - MSN
Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last? - MSN
Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study - MSN
Should You Buy Ionis Pharmaceuticals (IONS) After Golden Cross? - Zacks Investment Research
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Shares Climb 28% But Its Business Is Yet to Catch Up - simplywall.st
Ionis Pharmaceuticals Surges Amid Promising SMA Treatment Progress - StocksToTrade
Ionis Pharmaceuticals Advances as Barclays Upgrades Stock - timothysykes.com
Ionis Pharmaceuticals shares surge 8.89% intraday after Barclays analyst upgrades rating to 'Overweight'. - AInvest
10 Analysts Assess Ionis Pharmaceuticals: What You Need To Know - Nasdaq
Ionis Pharmaceuticals Inc (IONS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ionis Pharmaceuticals Inc 주식 (IONS) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
YANG MICHAEL J. | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
6,010 |
WENDER JOSEPH H | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
136,835 |
PARSHALL B LYNNE | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
91,344 |
HERMAN JOAN E | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
46,086 |
Hayden Michael R | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
54,298 |
Diaz Allene M. | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
19,795 |
BERTHELSEN SPENCER R | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
156,013 |
Monia Brett P | Chief Executive Officer |
Jul 11 '25 |
Sale |
41.74 |
1,160 |
48,416 |
179,820 |
Hayden Michael R | Director |
May 01 '25 |
Buy |
31.86 |
15,000 |
477,900 |
50,219 |
Birchler Brian | EVP, Corp and Development Ops |
Apr 15 '25 |
Option Exercise |
0.00 |
1,875 |
0 |
57,340 |
자본화:
|
볼륨(24시간):